Scale -

  • Revenue is 27958 Rs Cr; Annual Growth is 23 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 14 %
  • Ebitda is 9240 Rs Cr; Annual Growth is 69 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 115 %
  • PBT is 2017 Rs Cr; Annual Growth is 71 %; Continuous Growth over 3 years; in Top Quartile
  • PAT is 5355 Rs Cr; Annual Growth is 62 %; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Revenue is 8217 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

Profitability -

  • PBDIT Margin is 33.05 %; Annual Growth is 37 %; Continuous Growth over 3 years; 5 Year CAGR is 89 %
  • PAT Margin is 19.15 %; Annual Growth is 32 %; Continuous Growth over 3 years
  • Quarterly Ebitda Margin is 30 %; in Top Quartile

Return -

  • ROCE is 30.58 %; Annual Growth is 44 %; Continuous Growth over 3 years; in Top Quartile
  • ROA is 13.9 %; Annual Growth is 24 %; Continuous Growth over 3 years; in Top Quartile
  • ROE is 23.75 %; Annual Growth is 25 %; Continuous Growth over 3 years; in Top Quartile

Efficiency -

  • Operating cash flow is 7334 Rs Cr; Annual Growth is 144 %; in Top Quartile; 5 Year CAGR is 111 %
  • Current Ratio is 1.9; Continuous Growth over 3 years
  • Quick Ratio is 1.42; Continuous Growth over 3 years
  • Inventory Turnover Ratio is 4.84; Continuous Growth over 3 years; 5 Year CAGR is 58 %

Solvancy -

  • Contingent Liabilities is 1666 Rs Cr; Annual Growth is 158 %; in Top Quartile
  • Total Debt is 5910 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Long term Debt is 1643 Rs Cr; in Top Quartile; 5 Year CAGR is 84 %

Quality -

  • Operating cashflow/ebitda is 79 %; Annual Growth is 45 %; in Top Quartile
  • Operating cashflow/PAT is 137 %; Annual Growth is 51 %; in Top Quartile
  • Current Tax/PAT is 29 %; Continuous Decline over 3 years
  • Exceptional Items/PBT is -8 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is -1 %; Annual Growth is 43 %; Continuous Growth over 3 years
  • Other Expenses/Total Expenses is 35 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Lupin Receives One USFDA Observation for Goa Facility
Read More
  • Past/current
Lupin Gets Tentative Nod To Market A Billion Dollar Blood Pressure Drug
Read More
  • Past/current
Lupin appoints Brian Savage as President, Chief Legal Officer
Read More
  • Past/current
Lupin Launches Generic Pain Relief Tablets In U.S.
Read More
  • Past/current
Lupin gets CDSCO nod for nivolumab biosimilar
Read More
  • Past/current
Lupin gets USFDA nod for generic vitamin K drug
Read More
  • Past/current
Lupin ESG rating falls to 70 in FY26 on lower social, governance scores
Read More
  • Past/current
Lupin receives USFDA approval for Phytonadione Injectable Emulsion
Read More
  • Past/current
Lupin Rises 2% After US FDA Nod for Vitamin K Injection
Read More
  • Past/current
Lupin gets US FDA nod for vitamin K injection with $52 million US market
Read More
  • Past/current
Lupin: ??????? ??????????? ????????????? ??????.. ???? ???????????? FDA ?????? ???????!
Read More
  • Past/current
Lupin Launches Formoflo-G® MDI, World’s First Fixed-dose Triple Combination Drug for COPD Management
Read More
  • Past/current